Company Encyclopedia
View More
name
KANGHUI PHARMACEUTICAL
603139.SH
Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. It offers gynecological, orthopedic, dermatology, diabetes, respiratory system, urinary system, cardiovascular, tranquilizer, gastrointestinal, hepatobiliary, and other drugs in the form of tablets, capsules, granules, mixtures, teas, plasters, ointments, liniments, lotions, and tinctures. The company was founded in 2009 and is based in Xianyang, China.
3.159 T
603139.SHMarket value -Rank by Market Cap -/-

Financial Score

06/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking219/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-22.48%E
    • Profit Margin-35.82%E
    • Gross Margin25.98%C
  • Growth ScoreE
    • Revenue YoY-15.21%E
    • Net Profit YoY-149.55%E
    • Total Assets YoY-6.02%D
    • Net Assets YoY-23.50%E
  • Cash ScoreE
    • Cash Flow Margin-279.17%D
    • OCF YoY-15.21%E
  • Operating ScoreD
    • Turnover0.26D
  • Debt ScoreD
    • Gearing Ratio60.48%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    KANGHUI PHARMACEUTICAL: The stock abbreviation has been changed to "KANGHUI CO., LTD."

    KANGHUI PHARMACEUTICAL announced that the company's stock abbreviation will change from "KANGHUI PHARMACEUTICAL" to "KANGHUI CO., LTD." The change date is September 29, 2025, and the stock code "603139" will remain unchanged. This abbreviation change aligns with the company's long-term development plan and helps the market better understand the company's development positioning, but it will not have a significant impact on the company's current operating performance. The company stated that this change complies with relevant laws, regulations, and the company's articles of association

    Zhitong·
    SH
    603139
    0.00%
    Zhitong·
    SH
    603139
    0.00%

    KANGHUI PHARMACEUTICAL plans to change its stock abbreviation to "KANGHUI CO., LTD."

    According to the announcement released by KANGHUI PHARMACEUTICAL, based on the company's long-term development plan, the company intends to change its stock abbreviation from "KANGHUI PHARMACEUTICAL" to "KANGHUI CO., LTD." The new stock abbreviation is concise and clear, retaining the core brand identifier "KANGHUI" while adding the words "CO., LTD." to help the market better understand the company's development positioning and assist investors in accurately grasping the company's core value and development direction

    Zhitong·
    SH
    603139
    0.00%
    Zhitong·
    SH
    603139
    0.00%

    KANGHUI PHARMACEUTICAL: Shareholder Chuangxiangying pledged 1.9976 million shares

    KANGHUI PHARMACEUTICAL announced that its shareholder holding more than 5%, Chuangxiangying, pledged 1,997,600 shares, accounting for 33.33% of its holdings in the company and 2% of the company's total share capital. The pledge registration date is September 9, 2025, with the pledgees being Xu Yipeng and Cui Xiangnan. The purpose of the pledged financing is to supplement working capital. As of the date of this announcement, Chuangxiangying has cumulatively pledged 3,995,200 shares of the company, accounting for 66.67% of its holdings and 4% of the company's total share capital

    Zhitong·
    SH
    603139
    0.00%
    Zhitong·
    SH
    603139
    0.00%

    KANGHUI PHARMACEUTICAL's subsidiary Shaanxi Youbang has suspended production

    KANGHUI PHARMACEUTICAL's subsidiary Shaanxi Youbang has decided to fully suspend production in Workshop 1, Workshop 2, and Workshop 3 due to intensified market competition and ongoing losses. The suspension aims to avoid further losses and protect shareholder interests. Shaanxi Youbang mainly produces chemical drug intermediates, with an expected net profit of -52.5128 million yuan in 2024, impacting the company's net profit attributable to shareholders by 29.88%. Future production resumption will be determined based on market conditions

    Zhitong·
    SH
    603139
    0.00%
    Zhitong·
    SH
    603139
    0.00%

    KANGHUI PHARMACEUTICAL released its performance for the first half of the year, with a net loss attributable to the parent company of 40.2036 million yuan, an increase of 362.01%

    KANGHUI PHARMACEUTICAL released its semi-annual report for 2025, with operating revenue of 248 million yuan, a year-on-year decrease of 6.83%. The net loss attributable to the parent company was 40.2036 million yuan, a year-on-year increase of 362.01%. The net loss after deducting non-recurring gains and losses was 42.8271 million yuan, a year-on-year increase of 167.89%. The basic loss per share was 0.4 yuan

    Zhitong·
    SH
    603139
    0.00%
    Zhitong·
    SH
    603139
    0.00%
    © 2025 Longbridge｜Disclaimer